Article Type: Case Reports
Atomoxetine Treatment in a Patient with the Comorbidity of Attention Deficit Hyperactivity Disorder and Fragile X Syndrome
Esra Okyar, Leyla Bozatli, Isik Gorker

Fragile X Syndrome is a genetic disease defined by cognitive and behavioral characteristics that accompany apparent physical features. Male individuals are affected by this syndrome more severely, and it is the most common cause of mental retardation in men. The most common accompanying psychiatric conditions are mental retardation, autism, Attention Deficit Hyperactivity Disorder (ADHD), anxiety disorder, depression, sleep disorders and aggression. Anxiety, depression, shyness and social withdrawal are more common in female individuals. The diagnosis and treatment of the ADHD and selective mutism in a female adolescent patient who was Fragile X full mutant will be discussed in this case report.


1.Ciaccio C, Fontana L, Milani D, Tabano S, Miozzo M, Esposito S. Fragile X syndrome: a review of clinical and molecular diagnoses. Ital J Pediatr 2017;43(1):39.

2.Saldarriaga W, Tassone F, Gonzalez-Teshima LY, Forero-Forero JV, Ayala-Zapata S, Hagerman R. Fragile X syndrome. Colomb Méd (Cali) 2014;45(4):190-8.

3.Lee AW, Ventola P, Budimirovic D, Berry-Kravis E, Visootsak J. Clinical development of targeted fragile X syndrome treatments: an industry perspective. Brain Sci 2018;8(12).

4.Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Moine H, Kooy RF, et al. Fragile X syndrome. Nat Rev Dis Primers 2017;3:17065.

5.Keysor CS, Mazzocco MM. A developmental approach to understanding fragile X syndrome in females. Microsc Res Tech 2002;57(3):179–86.

6.Talisa VB, Boyle L, Crafa D, Kaufmann WE. Autism and anxiety in males with Fragile X syndrome: an exploratory analysis of neurobehavioral profiles from a parent survey. Am J Med Genet A 2014;164A(5):1198–203.

7.Freund LS, Reiss AL, Abrams MT. Psychiatric disorders associated with fragile X in the young female. Pediatrics 1993;91(2):321-9.

8.Turk J. Fragile X syndrome: lifespan developmental implications for those without as well as with intellectual disability. Curr Opin Psychiatry 2011;24(5):387–97.

9.Indah Winarni T, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, et al. Sertraline may improve language developmental trajectory in young children with fragile X syndrome: A retrospective chart review. Autism Res Treat 2012;2012:104317.

10.Hagerman RJ, Polussa J. Treatment of the psychiatric problems associated with fragile X syndrome. Curr Opin Psychiatry 2015;28(2):107–12.

11.Hagerman RJ, Hills J, Scharfenaker S, Lewis H. Fragile X syndrome and selective mutism. Am J Med Genet 1999;83(4):313-7.

12.Kora M, Alyanak B, Mukaddes NM. Methylphenidate treatment in two cases with fragile-X syndrome who exhibited. Bulletin of Clinical Psychopharmacology 1999;9(3):170-2. [Turkish]

13.Hutchison SL, Ghuman JK, Ghuman HS, Karpov I, Schuster JM. Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Ther Adv Psychopharmacol 2016;6(5):317-4.

14.Snircova E, Marcincakova-Husarova V, Hrtanek I, Kulhan T, Ondrejkal I, Nosalova G. Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD. Pediatr Int 2016;58(6):476-81.

Key words: ADHD, atomoxetine, fragile X syndrome
Psychiatry and Behavioral Sciences 2019;9(4):195-197
Online ISSN: 2636-834X
Creative Commons License This work is licensed under a Creative Commons Attribution 3.0 Unported License